Shopping Cart
- Remove All
Your shopping cart is currently empty
Leminoprazole is an orally available H+,K(+)-ATPase inhibitor that protects gastric mucosal cells from various cellular damages.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $78 | In Stock | |
| 5 mg | $192 | In Stock | |
| 10 mg | $288 | In Stock | |
| 25 mg | $472 | In Stock | |
| 50 mg | $648 | In Stock | |
| 100 mg | $888 | In Stock |
| Description | Leminoprazole is an orally available H+,K(+)-ATPase inhibitor that protects gastric mucosal cells from various cellular damages. |
| Targets&IC50 | K+-ATPase:31 μM |
| In vitro | Leminoprazole, when given orally at doses of 10-100 mg/kg, was able to dose-dependently inhibit H+, K(+)-ATPase activity at 3 and 6 hours after administration. Specifically, Leminoprazole (60 mg/kg, p.o.) inhibited H+, K(+)-ATPase for a much longer duration than omeprazole (30 mg/kg, p.o.). In pylorus ligated rats, the inhibitory effect of Leminoprazole on gastric acid secretion and its inhibitory rate on H+, K(+)-ATPase activity showed a good correlation, suggesting that the inhibitory efficacy of Leminoprazole in inhibiting gastric acid secretion via H+, K(+)-ATPase activity is comparable to that of omeprazole. The inhibitory effect was comparable to that of omeprazole. In addition, Leminoprazole (100 mg/kg) directly inhibited H+, K(+)-ATPase activity even when administered intragastrically after pyloric ligation, demonstrating the ability of this compound to inhibit H+, K(+)-ATPase activity directly from the gastric lumen. Further studies showed that continuous administration of Leminoprazole (100 mg/kg, p.o.) for 2 or 4 weeks had the same inhibitory effect on H+, K(+)-ATPase as a single dose. |
| In vivo | Leminoprazole, when given orally at doses of 10-100 mg/kg, was able to dose-dependently inhibit H+, K(+)-ATPase activity at 3 and 6 hours after administration. Specifically, Leminoprazole (60 mg/kg, p.o.) inhibited H+, K(+)-ATPase for a much longer duration than omeprazole (30 mg/kg, p.o.). In pylorus ligated rats, the inhibitory effect of Leminoprazole on gastric acid secretion and its inhibitory rate on H+, K(+)-ATPase activity showed a good correlation, suggesting that the inhibitory efficacy of Leminoprazole in inhibiting gastric acid secretion via H+, K(+)-ATPase activity is comparable to that of omeprazole. The inhibitory effect was comparable to that of omeprazole. In addition, Leminoprazole (100 mg/kg) directly inhibited H+, K(+)-ATPase activity even when administered intragastrically after pyloric ligation, demonstrating the ability of this compound to inhibit H+, K(+)-ATPase activity directly from the gastric lumen. Further studies showed that continuous administration of Leminoprazole (100 mg/kg, p.o.) for 2 or 4 weeks had the same inhibitory effect on H+, K(+)-ATPase as a single dose. |
| Molecular Weight | 341.47 |
| Formula | C19H23N3OS |
| Cas No. | 104340-86-5 |
| Smiles | S(CC1=C(N(CC(C)C)C)C=CC=C1)(=O)C=2NC=3C(N2)=CC=CC3 |
| Relative Density. | 1.25g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 50 mg/mL (146.43 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.